We previously developed a distress tolerance (DT)-based treatment that showed promising results for smokers with a history of early lapse. In the current study, we conducted a randomized controlled trial of this DT treatment for a general population of smokers not limited to those with a history of early lapse. We randomized 116 participants (41% female) to DT or standard treatment (ST). Both treatments included 1 individual session during Week 1 followed by 7 group sessions during Weeks 2-9 (quit date at Session 4), two 20-min phone sessions, and 8 weeks of transdermal nicotine patch. Results indicated no significant differences between conditions in the primary outcome of biochemically verified 7-day point prevalence smoking abstinence or in time to 1st lapse. Verified abstinence rates in DT were 38.7%, 38.7%, 46.77%, 40.32%, 20.9%, and 17.7% versus 40.7%, 37.0%, 53.7%, 44.4%, 33.3%, and 22.2% in ST at 1, 2, 4, 8, 13, and 26 weeks postquit, respectively. Additionally, we found no significant moderators of treatment efficacy and few differences in treatment process variables. These findings stand somewhat in contrast to those in our previous study and other recent studies of similar acceptance-based treatments. However, differences in methodology, inclusion of nicotine replacement therapy in both treatment conditions, and strict inclusionϪexclusion criteria that excluded many smokers with affective vulnerabilities may underlie this discrepancy. Future research should evaluate the utility of DT and other acceptance-based treatments in populations with affective vulnerabilities who might specifically benefit from a DT-based approach.
Although 70% of smokers want to quit (Centers for Disease Control and Prevention [CDC] , 2011), approximately 95% who quit unassisted (Hughes, Keely, & Naud, 2004) and 70%-80% of those who receive pharmacological and/or behavioral treatment relapse within 1 year (Fiore et al., 2008) . Accumulating evidence has suggested that initial lapses occur very early regardless of treatment, with at least 50% smoking within the first week of a quit attempt (Ashare, Wileyto, Perkins, & Schnoll, 2013; Hughes et al., 2004) . In a recent large study of 1,429 smokers, 44% failed to quit for 7 consecutive days (Japuntich et al., 2011) .
Roles of Distress Tolerance and Experiential Avoidance in Smoking Lapse
Negative affect, which is a prominent feature of nicotine withdrawal (Hendricks, Ditre, Drobes, & Brandon, 2006; Hughes, Higgins, & Hatsukami, 1990) , has long been thought to be a key factor in the maintenance of substance use behavior (e.g., Khantzian, 1997) , including tobacco use (Baker, Piper, McCarthy, Majeskie, & Fiore, 2004; Leventhal & Zvolensky, 2015) . Numerous empirical studies have confirmed that negative affect, even independent of nicotine withdrawal, is a critical factor in smoking treatment outcomes and a primary precipitant of smoking lapse and relapse. In early studies, smokers consistently reported that relapse to smoking often occurred in situations involving negative moods such as anxiety, anger, and depression (Bliss, Garvey, Heinold, & Hitchcock, 1989; Brandon, Tiffany, Obremski, & Baker, 1990; Marlatt & Gordon, 1980; Shiffman, 1982) , and lapses in negative affect situations were more likely to lead to complete relapses (O'Connell & Martin, 1987) . Later prospective studies suggested that the severity of negative affect (Baker, Brandon, & Chassin, 2004; Covey, Glassman, & Stetner, 1990; Ginsberg, Hall, Reus, & Muñoz, 1995; Kinnunen, Doherty, Militello, & Garvey, 1996; Piasecki, Kenford, Smith, Fiore, & Baker, 1997; West, Hajek, & Belcher, 1989) and temporal variability in affective symptoms (al'Absi, Hatsukami, Davis, & Wittmers, 2004; Brandon et al., 2003; Kenford et al., 2002; McCarthy, Piasecki, Fiore, & Baker, 2006; Piasecki et al., 2000; Strasser et al., 2005) are more robustly related to smoking cessation outcomes than are severity or variability in other withdrawal factor domains. More recent work has used methodology such as ecological momentary assessment to sample participants' mood and smoking behavior throughout the day in real time, which has revealed acute temporal relationships between negative affect and smoking lapse and relapse (e.g., Lam et al., 2014; Minami, Frank, Bold, & McCarthy, 2018; Minami, Yeh, Bold, Chapman, & McCarthy, 2014; Shiffman, 2005; Shiffman et al., 2007) .
Extending this work, further research has demonstrated that one's ability to tolerate affective distress (i.e., distress tolerance [DT] ), that is, to persist at maintaining abstinence despite encountering various states of affective discomfort, may also be a key determinant of successful long-term cessation (e.g., Brandon et al., 2003; Brown, Lejuez, Kahler, & Strong, 2002) . From this perspective, it is not simply the absolute magnitude of affective distress experienced but rather how one responds to this distress that may be critical in determining the outcome of a quit attempt. Indeed, evidence has suggested that smokers are less persistent than nonsmokers on tasks that produce affective and/or physical distress (e.g., breath-holding, mental arithmetic, tracing geometric figures from the perspective of a mirror; Brown et al., 2002; Quinn, Brandon, & Copeland, 1996) , and within smokers, the duration of persistence on these tasks prospectively predicts abstinence following a quit attempt (Brandon et al., 2003; Brown et al., 2009) .
Other recent research has focused on the related concept of experiential avoidance, which occurs when a person is unwilling to remain in contact with particular private experiences (e.g., bodily sensations, emotions, thoughts, memories, behavioral dispositions) and takes steps to alter the form or frequency of these events and the contexts that occasion them, even when doing so creates harm. (Hayes, 2004, p. 14) Efforts to control or suppress private experience may be a problematic method of coping for smokers who, in an effort to escape the uncomfortable negative affect and symptoms of nicotine withdrawal, may readily resort to the calming effects of nicotine (Piasecki, Fiore, & Baker, 1998) for relief. Recent work has demonstrated that higher levels of smoking-specific experiential avoidance are associated with greater reliance on cigarettes and affect-regulatory smoking outcome experiences (Farris, Zvolensky, & Schmidt, 2015) . Additionally, smoking-specific experiential avoidance is associated with greater negative affect, craving, and nicotine withdrawal at the initiation of smoking cessation treatment (Farris, Zvolensky, & Schmidt, 2015) . Further, in the context of experiencing internal distress while quitting (e.g., negative affect, physical withdrawal symptoms), high experientially avoidant smokers are at an increased likelihood of smoking lapse, even after smoking cessation treatment, relative to smokers with low levels of experiential avoidance (Minami, Bloom, Reed, Hayes, & Brown, 2015) . Reductions in experiential avoidance by quit date are also associated with increased likelihood of quit date abstinence and are predictive of lower levels of internal distress on quit day (Farris, Zvolensky, & Schmidt, 2015) .
Distress Tolerance Treatment for Smoking Cessation
Taken together, evidence from research findings in distress tolerance and experiential avoidance has indicated that how one responds to affective distress is a significant predictor of smoking relapse. These findings are distinct in their emphasis on the regulation of and sensitivity to affect, rather than solely on the level of affective symptoms being reported or expressed, and led us to develop a distress tolerance (DT)-based treatment for smoking cessation. We have conducted a small, randomized controlled trial of this DT treatment in a sample of smokers with a history of early lapses (all participants had not attained more than 3 days of abstinence during the previous 10 years; Brown et al., 2008 Brown et al., , 2013 . Results showed that compared to standard treatment (ST), participants who received the DT treatment showed a larger decrease in smoking-specific experiential avoidance between baseline and quit date, were 6.46 times more likely to be abstinent at the end of treatment (66.7% vs. 31.8%), and were also much more likely to recover from early lapses (Brown et al., 2013) . However, smoking outcomes were not significantly different between conditions at posttreatment follow-ups (8, 13, and 26 weeks postquit).
This DT treatment has at its core the systematic and repeated exposure to increasingly lengthy periods of smoking abstinence prior to quit date. This was accomplished by prescribing specific periods of smoking abstinence of increasing duration over time.
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Treatment sessions were focused on the practice of DT skills used to manage the affective distress experienced. Participants needed to demonstrate a willingness to engage fully in this exposure experience. An acceptance of the discomfort and distress involved as they worked toward their desired goal of quitting smoking was encouraged. Attempts to use distraction procedures or "control strategies" that promote experiential avoidance were discouraged, given these strategies have been shown to be significantly less effective than is focused exposure in the treatment of anxiety disorders (Craske, Street, & Barlow, 1989; Grayson, Foa, & Steketee, 1982) . Therefore, we also provided training in skills derived from acceptance and commitment therapy (ACT; Hayes, Strosahl, & Wilson, 1999) , which is designed to facilitate acceptance behaviors aimed at private events that have interfered with accomplishing life goals and approach of psychologically aversive or troubling internal stimuli while behaving adaptively (Gifford, 1994; Gifford & Hayes, 1997) . Ideally, smokers learned that controlling negative affect and avoiding thinking certain thoughts may simply not be a feasible permanent solution.
The Current Study
Although it is evident that a low level of distress tolerance is predictive of early smoking lapse (Brandon et al., 2003; Brown et al., 2002 Brown et al., , 2009 , it is not as evident that this translates to the identification of individuals who, across multiple quit attempts over time, are consistently characterized by a history of early lapses. Furthermore, recent trials of ACT-based treatment for smoking cessation that were not limited to smokers with a history of early lapses have shown positive outcomes (Bricker, Bush, Zbikowski, Mercer, & Heffner, 2014; Bricker, Mann, Marek, Liu, & Peterson, 2010; Bricker, Wyszynski, Comstock, & Heffner, 2013; Gifford et al., 2004 Gifford et al., , 2011 Hernández-López, Luciano, Bricker, Roales-Nieto, & Montesinos, 2009) . Therefore, in the current study, we conducted a randomized controlled trial of our DT treatment in a general population of cigarette smokers (i.e., not restricted only to smokers with a history of early lapses), with standard behavioral treatment (ST) matched for contact time serving as the comparison condition. All participants in both groups also received a standard 8-week course of transdermal nicotine patch (TNP). We hypothesized that the behavioral exposure and training in distress tolerance skills in our DT treatment would be more efficacious in ameliorating withdrawal-related relapse risk than would ST. We also tested the hypotheses that participants randomized to the DT treatment would experience (a) greater increases in task persistence and greater decreases in emotional avoidance during the prequit period and (b) lower levels of negative affect on quit date.
Method Participants
Adult smokers were recruited from the local community via newspaper and radio advertisements. Eligible individuals were between 18 and 65 years of age, had smoked at least 10 cigarettes per day for the past 3 years, and were motivated to quit smoking (at least 5 on a 10-point scale). Exclusion criteria were current Axis I disorder according to the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; American Psychiatric Association, 1994); nonnicotine substance abuse or dependence within the past 6 months; current use of psychotropic medication; history of a significant medical condition (e.g., cardiovascular, neurologic, gastrointestinal, other systemic illness); or deemed as currently unhealthy in the context of a brief physician screening, pregnancy or breastfeeding, or current use of pharmacotherapy for smoking cessation or other tobacco products.
Interested individuals were first screened via telephone; those who met preliminary criteria were scheduled for a more comprehensive baseline assessment at our Butler Hospital research laboratory, during which they provided informed consent and completed a diagnostic interview (Mini-International Neuropsychiatric Interview; Sheehan et al., 1998) to confirm their eligibility. The CONSORT flow diagram is shown in Figure 1 . The Institutional Review Board at Butler Hospital approved this study.
Procedure
The anticipated number and size of the behavioral treatment groups were determined in advance, and each group's treatment assignment was randomly selected from the fixed pool of possible assignments by an individual who had no contact with the participants. Participants were informed of their treatment assignment upon arrival to their first session; therefore, all randomized participants received their assigned treatment. Detailed therapist manuals were used to ensure standardized delivery of the treatments. The therapists were master's-level clinicians (social worker, nurse) and psychology trainees (predoctoral students). Therapists were paired; each pair served as cotherapists for groups in both treatment conditions. The senior author (Richard A. Brown) and second author (Kathleen M. Palm Reed) trained the therapists and conducted weekly group supervision sessions to ensure standardization of protocol delivery. All sessions were conducted in our research laboratory at Butler Hospital and videotaped to facilitate supervision; therapists were provided detailed written feedback each week by Kathleen M. Palm Reed.
Treatment Conditions
The standard treatment (ST) and distress tolerance (DT) treatment conditions were matched on time and structure. Both were delivered over a 9-week period beginning with one 1-hr individual session during Week 1, followed by seven 2-hr group sessions during Weeks 2-9, with quit date at group Session 4. Additionally, all participants received two 20-min phone sessions: between Session 4 (the quit date session) and Session 5, and between Sessions 6 and 7 (during the week without a group session). All participants (ST and DT) began using transdermal nicotine patch (TNP) on their quit date and continued for 4 weeks on a 21-mg patch, then tapered to 14 mg for 2 weeks, and finally 7 mg for 2 weeks.
Standard smoking cessation treatment (ST). ST was based upon a standard behavioral protocol (Brown, 2003) that has yielded positive outcomes in controlled trials (Brown et al., 2001) and was consistent with the most recent clinical practice guideline from the U.S. Department of Health and Human Services (Fiore et al., 2008) . During the individual session, therapists established This document is copyrighted by the American Psychological Association or one of its allied publishers.
rapport, provided support and encouragement, engaged participants in a discussion of previous quit experiences, and provided an overview of ST. The prequit and quit date group sessions focused on preparation for quit date, reinforcement and support for quitting, discussion of past quit experiences, initiation of self-monitoring, identification of triggers, development of selfmanagement skills as coping strategies for triggers (three As: avoid, alter, alternative), avoidance of alcohol use, enlisting social support, and instruction in use of TNP. During the quit date session, participants received individual support and the opportunity for more tailored and elaborate discussions of quitting experiences and coping strategies. After quit date, remaining sessions focused on relapse prevention, including ongoing discussion of quitting experiences, anticipation of high-risk situations, developing social support, and initiating lifestyle changes that support abstinence.
Distress tolerance (DT) treatment.
A detailed description of our original DT treatment for smokers with a history of early lapse has been published previously (Brown et al., 2008 (Brown et al., , 2013 . The DT treatment in the current study included the same elements, but the structure and duration of the sessions were changed to match the ST protocol as described earlier (one 1-hr individual session, seven 2-hr group sessions, and two 20-min phone sessions). Participants in DT engaged in exercises aimed at increasing their tolerance of distress while maintaining a focus on the valued life goals associated with quitting smoking. The individual session served to increase motivation and foster the therapeutic relationship through values assessment and clarification and assessment of the phenomenology of participants' past quit attempts. Prequit date sessions focused on increasing exposure to withdrawal-related distress via nicotine fading (Foxx & Brown, 1979) and increasing periods of scheduled abstinence, along with exercises and metaphors to illustrate the concepts of acceptance and defusion. DT also included the major elements of ST (e.g., self-management skills, instruction in use of nicotine replacement therapy (NRT), increasing social support, identifying high-risk situations, and avoiding lapses). However, given that DT and ST were matched on time, the amount of time devoted to some ST elements was shortened in DT to make room for the additional metaphors and experiential exercises drawn from ACT to demonstrate concepts of willingness, assertiveness, values, and committed action. Furthermore, some ST elements in DT were conveyed with slightly different wording to ensure consistency and smooth transitions with the ACT-based content. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
When originally developing DT (Brown et al., 2008 (Brown et al., , 2013 , we had some concern that reducing withdrawal-related distress via pharmacotherapy (i.e., TNP) might paradoxically reduce the efficacy of DT, given its focus on tolerating distress. However, we also recognized that there would be abundant distress to be experienced prior to quit date (i.e., prior to the use of TNP) via nicotine fading. Furthermore, pharmacotherapy is recommended for all smokers by the current clinical practice guidelines (Fiore et al., 2008) . Finally, given that we found a significant treatment effect in our previous trial in which all participants received TNP (Brown et al., 2013) , we retained TNP in the current study.
Measures
Assessment of the primary outcome (smoking status) occurred at baseline, during behavioral treatment (1, 2, and 4 weeks postquit), and at 8, 13, and 26 weeks postquit follow-ups, with 96%, 96%, and 92% follow-up completion rates, respectively. Negative affect was also measured at these timepoints. Distress tolerance was measured at baseline and at a "prequit" assessment during the week prior to the scheduled quit date. Other process measures described in the next sections were completed at baseline, prequit, end of behavioral treatment (4 weeks postquit), and follow-ups. Participants were paid $40 for the prequit assessment; $25 for the end of treatment, 8, and 13 weeks postquit assessments; and $50 for the 26 weeks postquit assessment. They received an additional $30 for providing biochemical verification of abstinence (expired carbon monoxide [CO] and/or saliva cotinine; see later) at 8, 13, and 26 weeks. Assessors were blinded to treatment condition at the baseline assessment but could not be blinded for follow-ups because they were present at the beginning of group sessions to administer assessments. Nevertheless, during follow-ups the assessors would be aware of the participant's condition only if they specifically remembered it or the participant said something that revealed the condition. The participant's condition was not written on any assessment materials.
Smoking status. Self-reports of past-week abstinence (7-day point prevalence) were verified by expired carbon monoxide (CO; Ͻ8 ppm) at 1, 2, 4, 8, 13, and 26 weeks postquit and by saliva cotinine (10 ng/ml or less) at 13 and 26 weeks. When CO was unavailable for an assessment, self-reported abstinence was verified by informants identified by participants prior to quitting when possible (n ϭ 1 at Weeks 8 and 13). Unverified reports of abstinence were regarded as smoking.
Process measures. Distress tolerance. As in previous studies, distress tolerance was operationalized as duration of persistence on the computerized mirror tracing persistence task (C-MTPT), which requires that participants trace geometric figures from the perspective of a mirror (Strong et al., 2003) , and the paced auditory serial audition task (PASAT), which requires participants to engage in increasingly difficult mental arithmetic . Participants were asked to complete tasks to the best of their ability but were not provided with any incentives to do so.
Experiential avoidance. General tendency toward experiential avoidance was assessed using the 10-item version of the Acceptance and Action QuestionnaireϪII (AAQ-II; Bond et al., 2011; Cronbach's alpha ϭ .80) and the eight-item AvoidanceϪ Rumination subscale of the Behavioral Activation for Depression Scale (BADS-AR; Kanter, Mulick, Busch, Berlin, & Martell, 2007;  Cronbach's alpha ϭ .87). We also assessed smokingspecific experiential avoidance with the Avoidance and Inflexibility Scale (AIS; Cronbach's alpha ϭ .89), a 13-item measure designed to assess the likelihood that smoking-related internal experiences (e.g., thoughts of smoking, cravings, physical withdrawal) will lead one to smoke and the degree to which one believes that reduction in the frequency and intensity of these internal experiences (i.e., avoidance of them) is necessary in order not to smoke (Gifford, Antonuccio, Kohlenberg, Hayes, & Piasecki, 2002) .
Negative affect. Measures of negative affect included the affective withdrawal subscale of the Minnesota Nicotine Withdrawal Scale (MNWS; Hughes & Hatsukami, 1986 ; Cronbach's alpha ϭ .77) to assess withdrawal-related negative affect and the Negative Affect subscale of the Positive and Negative Affect Scale (PANAS; Watson, Clark, & Tellegen, 1988;  Cronbach's alpha ϭ .87, respectively) to assess general negative affect.
Treatment adherence. A modified version of the ACT Tape Rating Scale (Gifford & Hayes, 1998) , created to map onto the DT treatment manual, was used to rate adherence for the DT group sessions. A rating scale for ST was developed in a similar manner. All groups sessions were videotaped, and 35% of the tapes (both the DT and ST group sessions) were randomly selected for rating. Two raters independently assessed the presence or absence of therapists' behaviors that were categorized as "prescribed" (e.g., in-session exposure exercise; discussion of awareness, acceptance, and willingness to experience-for the DT sessions) and "proscribed" (e.g., discussion of values and goals, experiential acceptance, discussing how efforts to control thoughts and feelings do not work-for the ST sessions; Waltz, Addis, Koerner, & Jacobson, 1993) . Treatment adherence ratings indicated that 100% of prescribed elements were present in the DT tapes and the ST tapes that were rated, whereas no proscribed behaviors in ST session tapes were observed, indicating good treatment integrity in both treatment conditions. There was no disagreement between the two raters.
Data Analysis
Sample size estimation. We wanted to ensure an ability to detect a clinically meaningful increase in quit rates for DT of 10% over ST. To increase power and accurately reflect the planned analysis for the longitudinal design, we estimated sample size based on an analysis of all planned assessments of the primary outcome (7-day point prevalence smoking abstinence) through the last follow-up. We relied on outcomes from our previous trial (Brown et al., 2013) to estimate effects during the active treatment period and extrapolated long-term outcomes for the ST comparison condition using data from the current Clinical Practice Guideline for the treatment of tobacco dependence (Fiore et al., 2008) . Our original power analysis indicated that 101 participants per group would be required. However, after the study was initiated, the sponsor reduced the budget and we reached an agreement to reduce the target sample size to 128. We were able to recruit a final sample of 116 within the budget and time constraints determined by the sponsor.
Primary outcome. The effects of DT treatment on verified 7-day point prevalence abstinence through 26 weeks follow-up This document is copyrighted by the American Psychological Association or one of its allied publishers.
was tested using generalized estimating equations (GEEs). All randomized participants were included in these analyses; participants lost to follow-up were considered smoking. Planned baseline covariates included gender, age, baseline nicotine dependence, and time (weeks from quit date). An autoregressive (AR-1) correlation structure was specified in the GEE models because model fit indices (quasi-likelihood under the independence model criterion) indicated that AR-1 correlation structure fit the data best, compared to either an "independence" or "unstructured" correlation structure. Furthermore, we explored potential moderators of treatment efficacy by including baseline values of process measures (i.e., AAQ-II, AIS, MTPT, PASAT) as well as Treatment ϫ Process Measure interaction terms (e.g., Treatment ϫ AAQ-II) in the GEE primary outcome model separately, controlling for the same planned covariates. Secondary outcomes. Cox proportional-hazards regression analyses were conducted to test whether latency to first smoking lapse and latency to relapse (7 consecutive smoking days) differed between treatment conditions, controlling for gender, age, and nicotine dependence. All randomized participants were included in the analysis; those who never lapsed or relapsed were treated as censored in analyses. We used linear regression analysis to evaluate effects of treatment on process measures (task persistence, emotional avoidance, and negative affect), controlling for the corresponding baseline score. Sample sizes for these analyses varied based on available data and ranged from 75 (quit date affective withdrawal) to 112 (moderator analysis with AAQ-II).
Results

Preliminary Analyses
A total of 116 participants (41% female, 90.5% White, mean age ϭ 46.06 years) were randomized to receive distress tolerance treatment (DT; n ϭ 62) or standard treatment (ST; n ϭ 54). Prior to treatment, participants reported smoking 20.10 (SD ϭ 7.85) cigarettes per day and had a mean Fagerström Test of Nicotine Dependence of 5.7 (SD ϭ 2.04), indicating a moderate level of nicotine dependence. Table 1 presents demographic and baseline characteristics for each treatment group. Treatment groups did not differ on any baseline variables except that the DT group reported marginally higher baseline general emotional avoidance (AAQ-II) compared to the ST group (Ms ϭ 57.9 and 54.9, SDs ϭ 7.8 and 9.6, respectively, p ϭ .066).
Smoking Outcomes
The GEE models first examined the effects of planned covariates on smoking outcome along with the linear effect of time. 
Gender ( Note. DT ϭ distress tolerance; ST ϭ standard treatment; FTND ϭ Fagerstrom Test of Nicotine Dependence; C-MTPT ϭ computerized mirror tracing persistence task; PASAT ϭ paced auditory serial addition task; AAQ-II ϭ Acceptance and Action QuestionnaireϪII; AIS ϭ Avoidance and Inflexibility Scale; BADS-AR ϭ AvoidanceϪRumination subscale of the Behavioral Activation for Depression Scale; PANAS ϭ Positive and Negative Affect Scale; MNWS ϭ Minnesota Nicotine Withdrawal Scale. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Treatment was not significant (ps Ͼ .19). Additionally, abstinence rates were not significantly different for DT and ST participants at any of the individual assessment points (ps Ͼ .05).
Latency to First Lapse and Relapse
We also examined the effects of treatment on latency to first smoking lapse and relapse using Cox proportional hazard regression, controlling for the primary covariates of age, gender, and nicotine dependence. The observed median time to first lapse was 11.5 days (M ϭ 57.8 days, SD ϭ 73.5) in DT and 20 days (M ϭ 68.9 days, SD ϭ 79.2) in ST, whereas median time to relapse was 63 days (M ϭ 84.4 days, SD ϭ 76.5) in DT and 110.5 days (M ϭ 104.5 days, SD ϭ 76.1) in ST. However, no statistically significant difference in latency to first lapse (hazard ratio [HR] Including an adherence variable (1 ϭ attended all 7 groups sessions, 0 ϭ missed any sessions) in the primary outcome model discussed earlier showed that those who attended all seven group sessions were more likely to be abstinent (AOR ϭ 5.6, 95% CI [2.8, 11.1], p ϭ .000). However, a subsequent model with an Adherence ϫ Treatment interaction term revealed no moderating effect of adherence on treatment efficacy (AOR ϭ 1.21, 95% CI [.35, 4 .14], p ϭ .76).
Group Session Attendance and Nicotine Patch Use
On average, during the first 8 weeks, participants in the DT and ST groups used nicotine patches on 34.4 days (61.3%) and 35.3 days (63.0%), respectively. A total of nine participants (14.5%) in the DT group and 10 (18.5%) in the ST group never used patches during the study, whereas the majority of participants in both the DT and ST groups (64.5% and 61.1%, respectively) used them for at least 4 weeks (50%). In addition, 16 participants (25.8%) in the DT group and 13 (24.1%) in the ST group reported using patches after the initial 8 weeks postquit (for 13.8 days and 20.2 days on average, respectively). No significant differences across conditions were found in any of these adherence rates (ps Ͼ .30).
Potential Moderators
We also explored baseline scores on the AAQ-II, AIS, BADS-AR, C-MTPT, and PASAT as potential moderators in separate GEE models. However, no moderating effect of any of the variables on treatment efficacy was found (ps Ͼ .41).
Treatment Effects on Process Variables
Task persistence-Prequit changes. No difference in change from baseline to the prequit assessment in task persistence measured by the C-MTPT (range ϭ 14 -376; b ϭ 2.17, SE ϭ 16.17, p ϭ .89) or PASAT (range ϭ 1-347; b ϭ 23.76, SE ϭ 23.25, p ϭ .31) was found between conditions, controlling for the baseline score of the corresponding measure.
Experiential avoidance-Prequit changes. No difference in change from baseline to the prequit assessment in general experience avoidance (AAQ-II; b ϭ Ϫ1.16, SE ϭ 1.56, p ϭ .46) or smoking-specific experiential avoidance (AIS; b ϭ 1.04, SE ϭ 2.11, p ϭ .63) was found between conditions, controlling for baseline score of the corresponding measure. However, those in the ST condition reported significantly greater increases in rumination and avoidance (BADS-AR; b ϭ 3.17, SE ϭ 1.42, p ϭ .029) compared to those in the DT treatment (see Figure 2) .
Experiential avoidance-Postquit changes. No difference in change from baseline to end of behavioral treatment (4 weeks postquit) in general experience avoidance (AAQ-II; b ϭ 1.88, SE ϭ 1.62, p ϭ .25), smoking-specific experiential avoidance (AIS; b ϭ .95, SE ϭ 2.76, p ϭ .73), or rumination and avoidance (BADS-AR; b ϭ 2.04, SE ϭ 1.50, p ϭ .18) was found between conditions, controlling for baseline score of the corresponding measure.
Negative affect on quit date. Results showed that there was no significant difference between conditions in either affective withdrawal (MNWS) or negative affect (PANAS) on quit date (ps Ͼ .25), controlling for the corresponding baseline score.
Effects of Process Measures on Smoking Outcomes
Next, we examined whether changes in process measures (from baseline to the end of behavioral treatment at 4 weeks postquit) predicted smoking outcome at the end of pharmacotherapy (8 weeks postquit), controlling for age, gender, nicotine dependence, treatment condition, and baseline values of the corresponding variable. Logistic regression models showed that decreases in smoking-specific experiential avoidance (AIS; b ϭ Ϫ.072, SE ϭ .023, p ϭ .002) at the end of behavioral treatment significantly predicted increased odds of abstinence at 8 weeks postquit. However, changes in general experiential avoidance (AAQ-II; b ϭ .054, SE ϭ .034, p ϭ .11) and avoidance and rumination (BADS-AR; b ϭ .012, SE ϭ .037, p ϭ .73) were not associated with abstinence rates at 8 weeks postquit.
Exploratory Analysis: Early Lapsers
Finally, we explored whether the pattern of results for the primary smoking outcome changed when only early lapsers (defined as reporting no previous periods of abstinence longer than 72 hr prior to participating in this study) were included. Although these GEE models did not reach statistical significance due to the small sample size (n ϭ 18), they revealed that early lapsers in the DT treatment had almost twice the odds of abstinence over the first 4 weeks postquit compared to early lapsers in the ST treatment (AOR ϭ 1.97, 95% CI [.55, 7 .04], p ϭ .299) but not after 8 weeks postquit (see Figure 3 ). This pattern of results is consistent with that in our previous study (Brown et al., 2013) , which demonstrated the short-term efficacy of the DT treatment, compared to the ST treatment, among smokers with a history of early lapse (in that study, defined as no periods of abstinence longer than 72 hr in the previous 10 years). This document is copyrighted by the American Psychological Association or one of its allied publishers.
Discussion
A distress tolerance (DT) treatment for smoking cessation that combined elements of exposure, distress tolerance, and acceptance and commitment therapy (ACT; Hayes et al., 1999) , along with pharmacotherapy in the form of transdermal nicotine patch (TNP), did not improve short-term or prolonged smoking outcomes relative to standard behavioral treatment (ST) with TNP. There were no significant differences in abstinence rates between the two treatment groups at any time point. Further- This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
more, there were few group differences in hypothesized process measures, but decreases in smoking-specific experiential avoidance between baseline and end of treatment (4 weeks postquit) did predict successful cessation at 8 weeks postquit. In contrast, our previous study (Brown et al., 2013) of smokers with a history of early lapse found a significant treatment effect. Also, in our previous study, individuals who received DT reported larger decreases in smoking-specific experiential avoidance between baseline and quit date, but prequit changes in smokingspecific experiential avoidance did not relate to smoking cessation outcomes at the end of treatment. At the same time, exploratory analysis in the current study suggested that the DT treatment may have had greater short-term efficacy than did ST within the small (n ϭ 18) subsample of participants who had a history of early lapse (had never quit for more than 72 hr prior to study participation). This finding is consistent with results from our previous trial in which all participants were early lapsers who had never quit for more than 72 hr in the past 10 years (Brown et al., 2008 (Brown et al., , 2013 and leaves open the possibility that our DT treatment may be more effective than ST for smokers with a history of early lapse but not for those without such a history. Furthermore, in the current study, the DT and ST treatments were matched on total contact time and structure (i.e., number of sessions), whereas in our previous trial with early lapsers, the DT treatment had more total contact time than did ST (six 50-min individual sessions and nine 2-hr group sessions vs. six 90-min group sessions, respectively). Thus, we are unable to determine with confidence whether the superior short-term efficacy of DT was due to differences in the treatment content or contact time, but it is possible that our DT treatment is likely to have benefit for early lapsers but not for a general population of smokers. The literature is not yet extensive enough to directly compare our DT treatment to related treatments, including ACT-based treatments for general populations of smokers (i.e., not limited to early lapsers; Bricker et al., 2014 Bricker et al., , 2010 Bricker et al., , 2013 Gifford et al., 2004 Gifford et al., , 2011 Hernández-López et al., 2009) . Excluding small pilots (Bricker et al., 2010) and nonrandomized studies (Hernández-López et al., 2009) , two prior studies have compared ACT to a medication-only treatment (Gifford et al., 2004 (Gifford et al., , 2011 . When ACT has been compared to another established behavioral treatment, some studies have not included pharmacotherapy (Bricker et al., 2013; Hernández-López et al., 2009) , which makes direct comparison difficult because medication may have improved outcomes in the comparison conditions. A study that evaluated telephone-based ACT and provided 2 weeks of NRT (Bricker et al., 2014) echoes some of the findings in the present study. It likewise did not find a significant difference in quit rate between the two treatments at 6 months follow-up (although the overall ACT quit rate [33%] was somewhat higher at 6 months). It also found outcome differences in subgroups that overlap with our findings for early lapsers. For example, there was a significant difference in outcomes at follow-up for those with a low initial acceptance of cravings. This similarity in the pattern of results suggests that researchers might usefully explore the impact of DT and other acceptance-based approaches with particularly difficult to treat subgroups.
Moderation of Treatment Effects and Treatment Process
Previous studies have found that ACT-based treatment resulted in greater decreases in smoking-specific experiential avoidance (AIS) that mediated the effects of the treatment on smoking outcome (Bricker et al., 2013; Gifford et al., 2004 Gifford et al., , 2011 . Other research has shown that smoking abstinence elicits reductions in smoking-specific experiential avoidance (Farris et al., 2016 ). In the current study, participants in the ST condition had significantly greater increases in a measure of rumination and avoidance (BADS-AR) compared to those in the DT treatment, but no differences in changes in AIS or other process measures were observed across treatments. With respect to the relationship between experiential avoidance and smoking outcomes, decreases in smoking-specific experiential avoidance at the end of behavioral treatment were significantly associated with abstinence at 8 weeks postquit. However, this relationship did not differ between treatment conditions, suggesting that the DT condition did not differentially affect smoking-specific experiential avoidance relative to ST, unlike in our previous DT study (Brown et al., 2013) , and therefore it is not surprising that smoking outcomes did not differ between DT and ST.
Limitations
The current study had a number of strengths, including a rigorous, randomized controlled trial design with treatment conditions matched on time and structure; however, there were also limitations that warrant acknowledgment. First, the study may have been underpowered, because we had to reduce the sample size from the original target. However, we believe it is very unlikely that lack of power explains why we did not find group differences in abstinence rates, given our effect sizes. Second, we excluded smokers with current psychiatric and substance use comorbidities. Relative to the general population, smoking prevalence among individuals with these comorbidities is substantially higher (CDC, 2013; Lasser et al., 2000) . Furthermore, these individuals have more difficulty in quitting successfully compared to the general population of smokers (Prochaska, Delucchi, & Hall, 2004) , indicating that many smokers with these comorbidities are likely to have a history of early lapse. Gifford and colleagues excluded smokers with psychiatric and/or substance use comorbidities (Gifford et al., 2004 (Gifford et al., , 2011 , whereas other studies of ACT-based treatments for smoking cessation did not (Bricker et al., 2010 (Bricker et al., , 2013 (Bricker et al., , 2014 Hernández-López et al., 2009) . Some of these studies have shown stronger differential outcomes in psychologically distressed participants, suggesting the need for more research in this area. Third, the DT treatment we tested in the current study (one 60-min individual session and seven 2-hr group sessions) differed in total duration and structure from our prior DT treatment (six 50-min individual sessions and nine 2-hr group sessions) for reasons previously described. Although in revising the duration and structure we intended to retain all the major content elements, it is possible that one or more critical elements were unintentionally removed. Finally, including TNP in the DT treatment may have conveyed an inconsistent message and reduced participants' opportunities for exposure and practice of DT skills, because the purpose of using TNP is to decrease discomfort and intensity of This document is copyrighted by the American Psychological Association or one of its allied publishers.
nicotine withdrawal symptoms and cravings. Indeed, long-term quit rates for ACT-based treatments in previous studies that did not include pharmacotherapy (Gifford et al., 2004; Hernández-López et al., 2009) were somewhat higher than in the current study. Finally, we did not collect compliance data on the extent to which participants engaged in the scheduled abstinence or nicotine fading procedures, thus limiting our ability to examine outcomes according to these treatment compliance indices.
Conclusion
In conclusion, in the current study we conducted a randomized controlled trial of distress tolerance treatment versus standard behavioral treatment for smoking cessation in a general population sample of healthy adult daily smokers. Results indicated no significant differences in efficacy between the two treatment conditions, no significant moderators of treatment efficacy, and few differences in treatment process variables. There was some indication of better outcomes for early lapsers, however, which comports with previous research and suggests a useful avenue of research exploration.
